Table 2.

Flow cytometry showing immune cell types associated with positive response to αPD1 or combined αPD1 + αCTLA4 therapy in CT26 tumour bearing mice. Percentages of T cell subpopulations across control groups, treatment responder (TR) arms, and all treatment non-responsive tumours (TNR) across all treatment arms. Data are shown as the mean % of cells ± S.D. and are representative of n = 5–10 mice/ group, * p < 0.05; ** p < 0.01, *** p < 0.001 comparing TR to TNR.

	CT26 Tumour-Infiltrating Immune Cells
Treatment Group	CD8+ % of CD3+	GZB+ CD8+ % of CD8+	CD8+ TEM % of CD8+	CD4+ TEM % of CD4+
Control	14.74 ± 5.38	34.02 ± 8.15	7.32 ± 4.53	7.25 ± 5.75
TR αPD1	21.35 ± 2.78 *	58.46 ± 7.96 *	54.61 ± 8.96 **	42.68 ± 9.65 *
αPD1 + αCTLA4	42.13 ± 7.35 ***	76.06 ± 9.20 **	77.67 ± 21.50 ***	66.81 ± 18.09 **
TNR	16.43 ± 4.61	40.66 ± 3.20	20.69 ± 8.26	23.09 ± 10.62